Global guidelines for the management of high-cardiovascular-risk patients include aggressive goals for low-density lipoprotein cholesterol (LDL-C). Statin therapy alone is often insufficient to reach goals and nonstatin options have limitations. Here, we tested the lipid-lowering effects of the cholesteryl ester transfer protein (CETP) inhibitor drug obicetrapib in a randomized, double-blind, placebo-controlled trial in dyslipidaemic patients (n = 120, median LDL-C 88 mg dl−1) with background high-intensity statin treatment (NCT04753606). Over the course of 8 weeks, treatment with 5 mg or 10 mg obicetrapib resulted in a significant decrease as compared with placebo in median LDL-C concentration (by up to 51%; P < 0.0001), the primary trial outcome. As compared with placebo, obicetrapib treatment also significantly (P < 0.0001) decreased apolipoprotein B (by up to 30%) and non-high-density lipoprotein cholesterol (non-HDL-C) concentration (by up to 44%), and significantly (P < 0.0001) increased HDL-C concentration (by up to 165%; the secondary trial outcomes) and had an acceptable safety profile. These results support the potential of obicetrapib to address an unmet medical need for high-cardiovascular-risk patients.
Elevated LDL-C is a major risk factor for atherosclerotic cardiovascular disease (ASCVD) and the cornerstone of risk-reduction strategies1,2. Statins are generally the drugs of first choice in treating dyslipidaemia but, despite treatment with high-intensity statins, a proportion of patients do not achieve acceptable LDL-C levels with statin monotherapy3. Recent results from GOULD, a prospective observational registry study of patients with ASCVD, showed that most had suboptimal LDL-C levels at baseline and just 17.1% had intensification of their lipid-lowering therapy after 2 years4. Furthermore, two thirds of these patients continued to have an LDL-C concentration >70 mg dl−1 (ref. 4). Results from DA VINCI, a cross-sectional, observational study in Europe, showed similar substantial gaps between clinical guidelines and clinical practice for lipid management5. Several adjunctive LDL-C-lowering drug therapies are available, such as ezetimibe, bempedoic acid and proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors. However, these have several limitations, such as limited LDL-C lowering, potential safety concerns and reduced patient access. Additional therapies that substantially reduce LDL-C, and have favorable safety and patient acceptability profiles, including convenience of oral dosing, are urgently needed.
Cholesteryl ester transfer protein (CETP), a plasma glycoprotein produced in the liver and adipose tissue that circulates in the blood bound primarily to HDL, mediates the transfer of cholesteryl esters from HDL to apolipoprotein (Apo) B-containing particles, for example, very low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) particles, in exchange for triglycerides (TGs)6,7,8. Inhibiting CETP raises HDL cholesterol (HDL-C) and, in the case of potent CETP inhibition, also lowers LDL-C6,7,8. Several CETP-inhibitor drugs have been developed, but, to date, none has received market authorization largely due to compound or study-related failures9. CETP-inhibiting therapies were originally developed based on the premise that increasing HDL-C levels would prevent cardiovascular events6,10,11. However, results from clinical trials and Mendelian randomization data have suggested that cardiovascular benefits are uniquely related to changes in the concentration of Apo-B-containing particles (including LDL particles)6,12.
Obicetrapib is a selective CETP inhibitor undergoing clinical development for reducing both LDL-C and the incidence of major adverse cardiovascular events3,4,5,6,7,8,9,10,11,12,13,14,15. CETP inhibition by obicetrapib in patients with mild dyslipidaemia (TULIP), a study of 364 subjects conducted in Denmark and the Netherlands, found that a daily dose of 10 mg obicetrapib in combination with moderate-intensity statins (20 mg atorvastatin or 10 mg rosuvastatin) for 12 weeks resulted in an incremental LDL-C reduction of up to 50% compared with statin monotherapy14.
In contrast to the results observed in TULIP, results from a Mendelian randomization analysis suggested that combined exposure to variants in the genes that encode the targets of CETP inhibitors and statins was associated with discordant reductions in LDL-C and Apo B levels, and that the corresponding risk reduction was proportional to Apo B but less proportional to LDL-C12. Thus, there was concern that the potential clinical benefit of obicetrapib, when specifically used in combination with high-intensity statins, might be attenuated12,16. Another concern relates to the fact that some data suggest that LDL-C lowering by CETP inhibitors cannot be reliably assessed by the Friedewald equation but instead requires preparative ultracentrifugation (PUC)17.
The primary objective of this trial was to evaluate the efficacy of 8-week dosing of obicetrapib 5 mg and 10 mg, compared with placebo, as an adjunct to high-intensity statin therapy for decreasing LDL-C and Apo B. The second objective was to evaluate other lipoprotein lipid and apolipoprotein responses, safety and tolerability profiles, and plasma concentrations of obicetrapib during treatment and for several weeks of follow up. Lastly, in this study we aimed to determine whether various quantitative measures of LDL-C levels produced differences in the treatment effects of CETP inhibition.
Of the 120 subjects randomized, 119 (99.2%) completed treatment; the modified intent-to-treat (mITT) population included all 120 subjects (Fig. 1). Subjects had a mean age of 61.8 years, were 55.8% male and 76.7% White, and had an average body mass index (BMI) of 31.1 kg m−2 (Table 1). All patients were treated with high-intensity statins. Most were taking atorvastatin 40 mg (54.2%), whereas 24.2%, 8.3% and 13.3% of subjects were taking atorvastatin 80 mg, rosuvastatin 20 mg and rosuvastatin 40 mg, respectively.
LDL-C, Apo B, HDL-C and lipoprotein(a) (Lp(a)) concentrations at baseline and after 4 and 8 weeks of treatment (only after 8 weeks of treatment for Lp(a)) are shown in Fig. 2, and lipoprotein, lipid, apolipoprotein and Lp(a) concentrations at baseline and percent changes from baseline to the end of treatment are presented in Table 2. Obicetrapib 5 mg and 10 mg each significantly reduced LDL-C compared with placebo (P < 0.0001). In the primary analysis, which used the Friedewald formula to calculate LDL-C, LDL-C was reduced from baseline by 42.9% and 45.7% for 5 mg and 10 mg obicetrapib, respectively, compared with 0.0% for placebo. Results for LDL-C measured by PUC (also called beta-quantification), which was conducted to evaluate potential discordant results using this ‘gold standard’ method for LDL-C determination, were comparable to those from the Friedewald formula: −41.5% and −50.8% for 5 mg and 10 mg obicetrapib, respectively, compared with −6.50% for placebo. In addition, we calculated the LDL-C reductions for the 5 mg and 10 mg doses of obicetrapib with the Martin–Hopkins equation, a recently published alternative to the Friedewald formula18, and they were comparable again to the beta-quantification results: −42.5% and −49.2%, respectively. Additional sensitivity analyses including mixed model repeated measures (MMRM) with imputation and analysis of covarianace (ANCOVA), produced similar results, as did analysis of the per protocol (PP) population (n = 117).
Obicetrapib 5 mg and 10 mg also significantly reduced Apo B by 24.4% and 29.8%, non-HDL-C by 38.9% and 44.4%, and Lp(a) by 33.8% and 56.5%, respectively, (P < 0.0001) and significantly increased HDL-C by 135% and 165% and Apo A1 by 44.6% and 47.8%, respectively, compared with placebo (P < 0.0001). TG and VLDL-C (measured by PUC; beta-quantification) were both mildly but significantly reduced by obicetrapib 5 mg compared with placebo (−11.0% and −11.5%, respectively) (P < 0.05), but the comparison of obicetrapib 10 mg with placebo was not significantly different (Table 2). A post-hoc analysis indicated that in individuals with baseline Apo B > 100 mg/dl, obicetrapib 10 mg yielded median Apo B reductions of 39% from baseline.
Treatment-emergent adverse events were reported by a total of 42 (35.0%) of the 120 subjects in the safety population: 15 subjects (37.5%) and 8 subjects (20.0%) in the obicetrapib 5 mg and 10 mg groups, respectively, compared with 19 subjects (47.5%) in the placebo group. The adverse events reported by at least two subjects in any treatment group are shown in Table 3. The most prevalent adverse events were gastrointestinal disorders (primarily nausea) and nervous system disorders (primarily headache). A majority of events were classified as mild or moderate in severity; 1 subject (2.5%) in the placebo group had a severe adverse event (Covid-19 pneumonia). Six events reported by 4 subjects (10.0%) in the placebo group, 2 events reported by 2 subjects (5.0%) in the obicetrapib 5 mg group and 1 event reported by 1 subject (2.5%) in the obicetrapib 10 mg group, were considered to be study-drug related. Two subjects (5.0%), both in the placebo group, had serious adverse events (1 had Covid-19 pneumonia (mentioned above) and 1 had a transient ischemic attack). Neither was considered related to the study drug. One subject (2.5%) in the placebo group had moderate arthralgia that led to discontinuation of the study drug but was not considered to be related to study drug. There were no signals in any laboratory parameters, that is, no clinically meaningful shifts in chemistry, hematology or urinalysis parameters, and no changes in vital signs in either obicetrapib treatment group compared with placebo.
Pharmacokinetic (PK) assessment following end of treatment showed that the drug was nearly completely cleared from circulation by 4–8 weeks post-treatment. Plasma obicetrapib levels decreased by medians of 92%, 98% and 99% at 4, 8 and 15 weeks after the end of treatment, respectively, in the obicetrapib 5 mg group, and by 93%, 98% and 99%, respectively, in the obicetrapib 10 mg group.
In this trial of subjects with dyslipidaemia (LDL-C > 70 mg dl−1) receiving high-intensity statin therapy (40 mg or 80 mg atorvastatin or 20 mg or 40 mg rosuvastatin), 8 weeks of add-on treatment of obicetrapib 5 mg and 10 mg significantly reduced LDL-C, Apo B, non-HDL-C and Lp(a), and significantly increased HDL-C and Apo A1. Maximum LDL-C reductions were already present after 4 weeks of treatment. In the TULIP study, patients with mild dyslipidaemia who received 1 mg, 2.5 mg, 5 mg or 10 mg obicetrapib for 12 weeks had LDL-C reductions of 27%, 33%, 45% and 45%, respectively, and those who received 10 mg obicetrapib plus 20 mg atorvastatin or plus 10 mg rosuvastatin had LDL-C reductions of 68% and 63%, respectively14. However, that study design made it impossible to calculate the additional LDL-C lowering that might be achieved with a given dose of obicetrapib on top of statin and, furthermore, did not examine the combination of obicetrapib with high-intensity statins. Thus, the present results extend beyond previous findings for obicetrapib administered as monotherapy and in combination with moderate-intensity statins to demonstrate its lipid-altering efficacy at both 5 mg and 10 mg doses in combination with high-intensity statins.
Evidence from randomized clinical trials and Mendelian randomization studies of lipid-altering therapies indicates a causal relationship between lowering LDL-C and reduced risk of ASCVD19. A Mendelian randomization analysis by Ference et al12 further examined the association between changes in lipoproteins and the risk of major cardiovascular events related to variants in the CETP gene alone and in combination with variants in the 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) gene. This analysis demonstrated that, when evaluated alone, the CETP score was associated with higher HDL-C, as well as lower LDL-C, concordantly lower Apo B and a correspondingly lower risk of major cardiovascular events, which was similar in magnitude to the relation between the HMGCR score and risk of major cardiovascular events per unit LDL-C (and Apo B) change. However, when the CETP score and the HMGCR score were combined, the CETP score was associated with the same LDL-C reduction, but an attenuated Apo B response and a corresponding attenuated nonsignificant cardiovascular risk. These results suggested that combined exposure to gene variants that reduced both CETP and HMG coenzyme A reductase was associated with discordant LDL-C and Apo B reductions, and that reducing risk of cardiovascular events was proportional to the effects on Apo B, and less so for LDL-C. The results from TULIP and ROSE contradict the supposition that combining obicetrapib with moderate and high-intensity statin might significantly attenuate Apo B lowering.
Previous turnover studies with stable isotopes have suggested that the Apo-B- and LDL-C-lowering effect of CETP inhibitors is the consequence of increased clearance of Apo-B-containing lipoproteins, whereas the Lp(a) lowering effect follows from a decreased synthesis of Apo(a)20,21.
Cardiovascular outcomes trials of CETP inhibitors, with the exception of the Randomized Evaluation of the Effects of Anacetrapib through Lipid Modification (REVEAL) trial, failed to demonstrate clinical benefit. It is now understood that those failures were compound specific, not drug-class specific9. Dalcetrapib sub-optimally reduced LDL-C, torcetrapib had off-target adverse effects, and evacetrapib had an insufficient duration of follow up for the modest absolute LDL-C difference to have sufficient impact on cardiovascular events6,9,16,22,23. In contrast, the REVEAL trial of 30,449 patients with ASCVD showed that anacetrapib added to statin therapy reduced LDL-C (direct measurement method) by 41% relative to placebo at 2 years, and significantly reduced risk of a first major coronary event (rate ratio 0.91, 95% confidence interval (CI) 0.85, 0.97) during the median follow up of 4.1 years9,24. In a subgroup of 2,000 patients in REVEAL, LDL-C was also analyzed using the PUC method. Results showed that the relative LDL-C reduction versus placebo was in fact substantially less than that measured by the direct assay, 17% versus 41%, which was compatible with the relative Apo B difference of 18%. Direct enzymatic assays, as well as the Friedewald formula, tend to underestimate true LDL-C concentrations only when LDL-C is very low. This can lead to an overestimation of the percentage change from baseline LDL-C17,25. The ROSE trial included a comparison of LDL-C results obtained using the Friedewald equation with PUC and also with the Martin–Hopkins equation. LDL-C values were comparable with each method, that is, within ~3–4 mg dl−1 of each other in the range of LDL-C levels observed in ROSE, which is an important finding divergent from preconceptions.
A multiple, ascending dose, phase 1 study of obicetrapib 1 mg, 2.5 mg, 5 mg, 10 mg and 25 mg, showed near-total inhibition of CETP with the 25 mg dose (99.4%) with differentiated and less inhibition between the 2.5 mg, 5 mg and 10 mg doses13. CETP activity was inhibited by 90.9% and 97.6%, respectively, for the 5 mg and 10 mg doses. The increase in CETP inhibition between obicetrapib 5 mg and 10 mg resulted in greater changes from baseline for LDL-C, non-HDL-C, Apo B, HDL-C and Lp(a). The 5 mg dose versus the 10 mg dose reduced Apo B by 24.4% versus 29.75%, respectively, increased HDL-C by 135.4% versus 165%, respectively and, finally, reduced Lp(a) by 33.8% versus 56.5%, respectively.
There is a marked difference in the CETP inhibitory potential of obicetrapib compared to anacetrapib and evacetrapib. At equipotent dosages obicetrapib reduces CETP activity to a greater extent than both anacetrapib and evacetrapib13,26,27,28. This is also the case for the phase 3 dose of obicetrapib (10 mg) compared with that of anacetrapib (100 mg). There are no data available on CETP inhibition for the phase 3 dose of evacetrapib (130 mg); however, results from the phase 1 multiple-ascending dose study of 100 mg evacetrapib indicate that it is significantly less potent than obicetrapib. These differences in the capacity to inhibit CETP also translate into the ability to raise HDL-C; obicetrapib 10 mg raises HDL-C by 169.9% compared with placebo, while 100 mg anacetrapib and 130 mg evaceptrapib raised HDL-C levels by 104% and 131.6%, respectively16,24.
A potential explanation for the potency of obicetrapib comes from a series of crystallography experiments showing that CETP inhibitors locate at the narrow N-terminal neck of the hydrophobic tunnel of CETP and can restrict the lipid flow through this tunnel29. Whereas these interactions between the CETP inhibitor and the opening of the tunnel are of a hydrophobic nature, there are also three polar residues in the center of the inhibitor-binding site, Gln-199, Ser-230 and His-232. The authors conclude that it might be possible to incorporate more hydrophilic groups into the structure of a CETP inhibitor that can then interact with these three polar amino acids to improve the binding and specificity of the compound while also improving the solubility of the CETP inhibitor. Indeed, by introducing hydrophilic structures into obicetrapib, it is the most polar of all CETP inhibitors and has a LogP of 4.9 versus 9.2 for anacetrapib and 7.9 for evacetrapib30. It also has better bioavailability and greater efficacy at lower doses. These biochemical differences between CETP inhibitors likely partly explain the large differences in potency.
A limitation of this trial includes the relatively homogeneous racial/ethnic composition of the population evaluated, making it difficult to generalize the results to the wider population. In this trial, obicetrapib therapy of 5 mg and 10 mg did not result in clinically important changes in laboratory parameters or vital signs but had an acceptable safety profile, confirming previous safety and tolerability findings14. Although a recent Mendelian randomization study claimed that CETP inhibition may ‘cause’ an increase in cases of age-related macular degeneration31, those conclusions were contrary to available clinical evidence to date, including the results from the REVEAL trial of anacetrapib24. Analyses of obicetrapib blood concentrations demonstrated that steady-state conditions were already achieved by 4 weeks and decreased substantially after the end of treatment. As a result, unlike anacetrapib, which demonstrated accumulation in adipose tissue, the terminal half-life of obicetrapib was adequate for once-a-day chronic dosing.
In conclusion, this study demonstrated the efficacy of obicetrapib 5 mg and 10 mg as an adjunct to high-intensity statins for robustly decreasing LDL-C, Apo B, non-HDL-C and Lp(a) and increasing HDL-C and Apo A1, compared with placebo, thus refuting the theory that such CETP-inhibitor-driven effects would be attenuated when used in combination with high-intensity statins. This trial also expanded the growing body of evidence to support the safety and tolerability of this specific CETP inhibitor13,14. In light of the unmet medical need for additional therapies to substantially reduce LDL-C in patients at high cardiovascular risk, the results from ROSE are promising. Additional phase 3 investigations including a cardiovascular outcomes trial are currently underway to further assess the safety and clinical benefits of obicetrapib.
This placebo-controlled, double-blind, randomized, phase 2 dose-finding study of obicetrapib was conducted from February 2021 to August 2021 (6 months) at 17 clinical research sites in the United States (see list of Principal Investigators in the Supplementary Note 1) in accordance with Good Clinical Practice guidelines, the Declaration of Helsinki (2000) and the US 21 Code of Federal Regulations. The trial was registered at ClinicalTrials.gov with the identifier NCT04753606. The protocol was approved by Advarra Institutional Review Board (Columbia, Maryland). The protocol and the statistical analysis plan are provided in Supplementary Note 2. All subjects provided informed consent before their enrollment in the study. There were seven clinic visits during the trial: a screening visit where subjects provided informed consent, a randomization visit up to 2 weeks after screening where subject eligibility was confirmed and subjects were randomized to treatment, visits at the midpoint (week 4) and end of treatment (week 8), a safety and PK follow-up visit 4 weeks after the conclusion of treatment, and additional PK follow-up visits at 8 and 15 weeks after the conclusion of treatment.
Subjects were randomized, using an automated interactive response technology system, in a 1:1:1 ratio to the following treatment groups: 5 mg obicetrapib (one 5 mg obicetrapib tablet plus one placebo tablet), 10 mg obicetrapib (two 5 mg obicetrapib tablets) or placebo (two placebo tablets). To ensure similar distribution of LDL-C values across all treatment groups, subjects were stratified at randomization according to their screening LDL-C level of ≥100 or <100 mg dl−1. Investigators, participants, the clinical research organization and the sponsor of the trial were blinded to all lipid results from randomization through database lock. Obicetrapib and placebo tablets were provided to the clinical research sites by New Amsterdam Pharma (Naarden, the Netherlands). Subjects were instructed to take the assigned study drug once daily throughout the 8-week treatment period at approximately the same time each morning, with food. On days when clinic visits were scheduled, study drugs were administered with food following the collection of the fasted blood samples. Participants were instructed to bring all their study-drug supply to the site at the clinic visits, where compliance was evaluated by counting unused tablets.
Subjects included men and women 18–75 years of age with fasting LDL-C > 70 mg dl−1 and TG < 400 mg dl−1 at screening, while receiving high-intensity statin therapy (atorvastatin 40 mg or 80 mg or rosuvastatin 20 mg or 40 mg) at a stable dose for at least the prior 8 weeks. Women enrolled were not pregnant or breastfeeding, and, if of childbearing potential, had a negative urine pregnancy test and agreed to use an effective method of avoiding pregnancy throughout the trial. Volunteers were excluded from participation if they had a BMI ≥ 40 kg m−2, clinically significant cardiovascular disease, glycated hemoglobin ≥10%, uncontrolled hypertension, active muscle disease or creatine kinase thrice the upper limit of normal, estimated glomerular filtration rate <60 ml min−1 (ref. 32). hepatic dysfunction, anemia or a recent history of malignancy or alcohol or drug abuse. Individuals who had been treated with a PCSK9 inhibitor within 10 weeks prior to randomization or bempedoic acid within 2 weeks prior to randomization were also excluded.
Blood samples were obtained under fasting conditions (~10 h, nothing by mouth except water and any essential medications) at each clinic visit throughout the trial. At screening, baseline, and 4 and 8 weeks of treatment, fasting samples were analyzed for a lipid profile by Medpace Reference Laboratory, Cincinnati, Ohio, using Beckman Coulter AU5800. For the primary analysis, LDL-C was calculated using the Friedewald calculation (total cholesterol minus HDL-C minus (TG/5)) at each time point, unless TG ≥ 400 mg dl−1 or LDL-C ≤ 50 mg dl−1, in which case LDL-C was measured directly by preparative ultracentrifugation33. LDL-C was also measured by PUC at baseline and at the end of treatment in all subjects (Beckman Coulter AU5800), and was calculated using the Martin–Hopkins equation18, a modified version of the Friedewald equation that uses a novel factor based on the patient’s individual non-HDL-C and TG values, instead of the fixed ratio of TG/5. Additional components measured in the fasting lipid profile included HDL-C, non-HDL-C (total cholesterol minus HDL-C), VLDL-C, TG, Apo B, Apo A1 and Lp(a). Apo B and Apo A1 were measured using a Siemens nephelometric analyser. Lp(a) was measured using Roche c502. Fasting blood samples were analyzed at each clinic visit for safety chemistry (including glycated hemoglobin at screening) and hematology profiles. At randomization, a blood sample was collected pre-dose for PK analyses, and subsequent post-dose PK samples were collected once at approximately the same time at each remaining clinic visit for measurement of plasma obicetrapib concentrations. Chemical analyses of obicetrapib were performed by liquid chromatography (Shimadzu LC-30 AD)/mass spectrometry (AB Sciex Triple Quad 5500 System).
AEs were monitored from the first dose of study treatment through the completion of the trial. Vital signs, including body temperature, heart rate and triplicate systolic and diastolic blood pressure measurements were taken from screening through the safety follow-up visits, with participants in the supine position after at least 10 min rest prior to measurements. Body weight and height were measured at screening and used to calculate BMI. A single-standard 12-lead electrocardiogram was performed at screening, and a physical examination was performed at screening and the conclusion of the treatment period.
A sample size of at least 108 evaluable participants (36 per treatment group) was determined to provide more than 90% power to detect a 30% difference in LDL-C reduction at week 8 (standard deviation of 15%) for each of the obicetrapib groups compared with placebo at a two-sided significance level of 0.025. A total of 120 subjects (n = 40 per treatment group) was randomized.
All statistical analyses were performed using SAS v.9.4 (SAS Institute, Cary, NC). The mITT population, defined as all participants in the ITT population who received at least one dose of any study drug and had a baseline value for the LDL-C assessment, was the primary population for the efficacy analyses. Efficacy was also analyzed in the ITT (all participants randomized) and PP populations (all participants in the mITT population who had a baseline value for the LDL-C assessment, had a week 8 LDL-C assessment, and did not experience a major protocol deviation with the potential to impact the primary efficacy endpoint) as supportive analyses. Safety analyses were performed in the safety population defined as all participants who received at least one dose of any study drug. PK analyses were performed in the PK population defined as all participants in the mITT population who had sufficient blood samples collected for valid estimation of PK parameters.
The primary efficacy analysis, percent change in Friedewald-calculated LDL-C from baseline to week 8, was performed using an MMRM approach, with SAS Proc Mixed. The analysis included fixed effects for treatment, visit and treatment-by-visit interaction, along with a covariate of the baseline value as a continuous covariate. The restricted maximum likelihood estimation approach was used with an unstructured covariance matrix. LS means, s.e. and two-sided 95% CIs for each treatment group and for the pairwise comparisons of each dose of obicetrapib with the placebo group were determined. Adjustment for multiple comparisons was made using Dunnett’s test. No imputation of missing data was performed for the primary efficacy endpoint analysis. The Shapiro–Wilk test was used to evaluate normality. Three sensitivity analyses were also performed for the primary efficacy endpoint: MMRM with imputation, ANCOVA and ANCOVA using LDL-C by PUC. Similar MMRM models as described for the primary efficacy analyses were used to analyze the other efficacy endpoints (that is, percent change from baseline to week 8 in Apo B, non-HDL-C, HDL-C, Apo A1, TG, VLDL-C and Lp(a)). No adjustment was made for multiplicity in testing these other endpoints, and no imputation was made.
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
The authors declare that all data supporting the findings of this analysis, collected by MedPace ClinTrack, are available within the article and its supplement. New Amsterdam Pharma is committed to sharing, with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review and panel on the basis of scientific merit. All data provided are anonymized to respect the privacy of patients who have participated in the trial, in line with applicable laws and regulations.
Arnett, D. K. et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 140, e596–e646 (2019).
Mach, F. et al. ESC Scientific Document Group. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J. 41, 111–188 (2020).
Packard, C., Chapman, M. J., Sibartie, M., Laufs, U. & Masana, L. Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges. Heart 107, 1369–1375 (2021).
Cannon, C. P. et al. for the GOULD Investigators. Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. JAMA Cardiol. 6, 1060–1068 (2021).
Ray, K. K. et al. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur. J. Prev. Cardiol. 28, 1279–1289 (2021).
Tall, A. R. & Rader, D. J. Trials and tribulations of CETP inhibitors. Circ. Res. 122, 106–112 (2018).
Shrestha, S., Wu, B. J., Guiney, L., Barter, P. J. & Rye, K. A. Cholesteryl ester transfer protein and its inhibitors. J. Lipid Res. 59, 772–783 (2018).
Banderjee, S. & De, A. Pathophysiology and inhibition of cholesteryl ester transfer protein for prevention of cardiovascular diseases: an update. Drug Discov. Today 26, 1759–1764 (2021).
Schmidt, A. F. et al. Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease. Nat. Commun. 12, 5640 (2021).
Voight, B. F. et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomization study. Lancet 380, 572–580 (2012).
Van Capelleveen, J. C. et al. Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses. J. Clin. Lipidol. 10, 1137–1144.e3 (2016).
Ference, B. A. et al. Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk. JAMA 318, 947–956 (2017).
Ford, J. et al. Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br. J. Clin. Pharmacol. 78, 498–508 (2014).
Hovingh, G. K. et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet 386, 452–460 (2015).
Nurmohamed, N. S., Navar, A. M. & Kastelein, J. J. P. New and emerging therapies for reduction of LDL-cholesterol and apolipoprotein B: JACC Focus Seminar 1/4. J. Am. Coll. Cardiol. 77, 1564–1575 (2021).
Lincoff, A. M. et al., for the ACCELERATE Investigators. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N. Engl. J. Med. 376, 1933–1942 (2017).
Davidson, M. et al. Measurement of LDL-C after treatment with CETP inhibitor anacetrapib. J. Lipid Res. 54, 467–472 (2013).
Martin, S. S. et al. Comparison of a novel method vs. the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA 310, 2061–2068 (2013).
Ference, B. A. et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur. Heart J. 38, 2459–2472 (2017).
Millar, J. S. et al. Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects. J. Clin. Invest. 126, 1603–1604 (2016).
Thomas, T. et al. CETP (cholesteryl ester transfer protein) inhibition with anacetrapib decreases production of lipoprotein(a) in mildly hypercholesterolemic subjects. Arterioscler. Thromb. Vasc. Biol. 37, 1770–1775 (2017).
Barter, P. J. et al. for the ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109–2122 (2007).
Schwartz, G. C. et al. Effects of dalcetrapib in patients with acute coronary syndrome. N. Engl. J. Med. 367, 2089–2099 (2012).
HPS3-TIMI55-REVEAL Collaborative Group. Effects of anacetrapib in patients with atherosclerotic vascular disease. N. Engl. J. Med. 377, 1217–1227 (2017).
Holmes, M. V. & Ala-Korpela, M. What is ‘LDL cholesterol’? Nat. Rev. Cardiol. 16, 197–198 (2019).
Krishna, R. et al. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Clin. Pharmacol. Ther. 84, 679–683 (2008).
Krishna, R. et al. Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br. J. Clin. Pharmacol. 68, 535–545 (2009).
Suico, J. G. et al. Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults. J. Pharm. Pharmacol. 66, 1576–1585 (2014).
Liu, S. et al. Crystal structures of cholesteryl ester transfer protein in complex with inhibitors. J. Am. Coll. Cardiol. 287, 37321–37329 (2012).
Nurmohamed, N.S. et al. Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents? Cardiovasc. Res. https://doi.org/10.1093/cvr/cvab350 (2021).
Nordestgaard, L. T. et al. Long-term benefits and harms associated with genetic cholesteryl ester transfer protein deficiency in the general population. JAMA Cardiol. 7, 55–64 (2022).
CKD-EPI equations for glomerular filtration rate (GFR). MDCalc https://www.mdcalc.com/ckd-epi-equations-glomerular-fibtration-rate-gfr (2020).
LDL calculated. MDCalc https://www.mdcalc.com/ldl-calculated (2020).
This trial was funded by New Amsterdam Pharma. We thank the contributions of the study patients, the dedicated study physicians and the New Amsterdam Pharma operations team.
S.J.N. has received research support from AstraZeneca, New Amsterdam Pharma, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, IntraReDx, Roche, Sanofi-Regeneron and LipoScience and is a consultant for AstraZeneca, Amarin, Akcea, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion and Boehringer Ingelheim. M.D. is Vice President of Research & Development for New Amsterdam Pharma. J.J.K. is employed part-time as Chief Scientific Officer by New Amsterdam Pharma and is an Emeritus Professor of Medicine at the University of Amsterdam, The Netherlands. S.P.R. is employed by MedPace, Inc. D.K. is employed as Chief Operating Officer by New Amsterdam Pharma. D.L.C. is employed as Senior Director of Clinical Operations by New Amsterdam Pharma. N.J.A. is employed by MedPace, Inc. M.H.D. is employed as Chief Executive Officer by New Amsterdam Pharma.
Peer review information
Nature Medicine thanks Gerald Watts and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editor: Michael Basson, in collaboration with the Nature Medicine team.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Nicholls, S.J., Ditmarsch, M., Kastelein, J.J. et al. Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. Nat Med 28, 1672–1678 (2022). https://doi.org/10.1038/s41591-022-01936-7